English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04837196 /

7517-CL-1101

A Phase 1/2, Open-Label Study Investigating The Safety, Tolerability And Efficacy Of ASP7517 As A Single Agent And In Combination With Pembrolizumab In Patients With Advanced Solid Tumors Known To Express WT1 Antigen

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: